Highlights & Insights

Nearly 90 percent of newly launched medicines are available in the United States.

Jointly issued by the American Cancer Society (ACS), the Centers for Disease Control and Prevention (CDC), the North American Association of Central Cancer Registries (NAACCR), and the National Cancer Institute (NCI).

In the last five years, 18 states have passed legislation requiring prescription drug manufacturers to disclose certain price information for their drugs.

With the U.S. FDA endorsing its 29th novel drug on June 30, the drug industry was slightly ahead of last year’s pace.

If the first quarter was quiet for takeovers the second saw M&A grind to a halt. What can the matter be?

Another July, another round of drug price hikes in America.

The Trump administration’s effort to require hospitals to disclose their rates in a “consumer-friendly format” was praised by patients and employers who worried the lack of transparency kept prices high.

“Extreme” drug price increases for antiparasitic medication were associated with increased total outpatient treatment costs, or TOCs.

This brief analyzes leading federal approaches to address Medicaid prescription drug spending, discusses (where available) a range of cost estimates for each policy, and assesses what drives those estimates or where there is uncertainty in them.

Medicaid, once considered the ugly duckling compared with the politically powerful and popular Medicare program, now covers nearly 1 in 4 Americans.

Some recent key findings on the American public’s experience with and perceptions of prescription drugs and their prices.

This analysis examines U.S. Medicaid outpatient prescription drug utilization and spending before rebates over the 2015 to 2019 period, which is helpful for understanding recent cost drivers and areas for targeted policy action.